ResultsIQ

ResultsIQ › Latest results › Gujarat Kidney And Super Speciality Limited

Gujarat Kidney And Super Speciality Limited Q2 FY27 results deck summary

NSE: GKSL · BSE: 544666

Results deck of 4 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue rose 194.6% YoY to ₹3,809 lakhs and EBITDA margin expanded to 26.8% from 24.4% in Q1 FY27.

Key takeaways

  1. Q2 revenue Revenue from operations was ₹3,809 lakhs in Q2 FY27, up 194.6% YoY from ₹1,293 lakhs and 11.1% QoQ from ₹3,429 lakhs.
  2. Margin risk EBITDA margin was 26.8% in Q2 FY27 against 39.6% in Q2 FY26, and employee costs rose 47.0% QoQ to ₹777 lakhs.

Original filing on BSE

Gujarat Kidney And Super Speciality Limited Q2 FY27 results

As filed: Revenue ₹38.1 cr, EBITDA ₹10.2 cr, PAT ₹6.6 cr, EBITDA margin 26.8%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹38.1 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹34.3 cr, EBITDA ₹8.4 cr, PAT ₹5.3 cr, EBITDA margin 24.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹34.3 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +25.4% in 28 days (Nifty 500: −3.1%).
  • Q4 FY26: Revenue ₹30.6 cr, EBITDA ₹6.3 cr, PAT ₹4.8 cr, EBITDA margin 20.6%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹30.6 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −5.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹23.3 cr, EBITDA ₹6.9 cr, PAT ₹3.7 cr, EBITDA margin 29.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹23.3 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −4.2% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gujarat Kidney And Super Speciality Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.